News

April 13, 2022

Vivace Therapeutics Presents New Preclinical Data Highlighting Strong Synergistic Activity for Combination of VT3989 and Osimertinib at American Association for Cancer Research (AACR) Annual Meeting 2022

Research and Publications

Publications and Presentations

March 7, 2013

The Hippo Pathway and Human Cancer

Publications and Presentations

November 5, 2015

Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer

News

June 28, 2017

Vivace Therapeutics Comes out of Stealth with $40 Million to Turn Novel Biology into First-in-Class Cancer Therapeutics